RxDoctor Payments Data

Margaret Perrin, MD

Neurology · Arlington, VANPI 1528281177

Payments from drug & device makers

$3,010in general payments, 2019–2025

Across 140 payments — averaging $21.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$766
  • Supernus Pharmaceuticals, Inc.$384
  • Pfizer$229
  • Sunovion Pharmaceuticals Inc.$179
  • Lilly USA, LLC$169
  • Genentech USA, Inc.$157
  • plus $1K from 20 others

What the payments were for

  • Speaking & faculty fees$171%
  • Food & beverage$2,98099%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,010 in reported general payments places this provider in the 55th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$97,240
Medicare patients
242
Services billed
509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ropinirole ErRopinirole Hcl19$2,933
Levetiracetam83$2,599
Memantine Hcl91$2,541
Memantine Hcl ErMemantine Hcl22$1,706
Duloxetine Hcl27$1,679
Donepezil Hcl149$1,285
Carbidopa-LevodopaCarbidopa/Levodopa31$1,198
Gabapentin64$1,045
Ropinirole Hcl15$911
Topiramate45$668
Oxcarbazepine11$535
Escitalopram Oxalate23$452
Bupropion Hcl SrBupropion Hcl23$334
Bupropion XlBupropion Hcl15$332
Nortriptyline Hcl19$296

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Upsher-smith Laboratories LLCTopiramate$18$66845 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 474 neurology providers in Virginia.

Other neurology in Arlington

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →